The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
T Barbui, J Thiele, H Gisslinger, HM Kvasnicka… - Blood cancer …, 2018 - nature.com
The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …
The international consensus classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms
J Thiele, HM Kvasnicka, A Orazi… - American journal of …, 2023 - Wiley Online Library
A group of international experts, including hematopathologists, oncologists, and geneticists
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …
were recently summoned (September 2021, Chicago, IL, USA) to update the 2016/17 World …
Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology
AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar… - Journal of the National …, 2022 - jnccn.org
The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …
Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy
CN Harrison, JS Garcia, TCP Somervaille… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
CN Harrison, AM Vannucchi, JJ Kiladjian, HK Al-Ali… - Leukemia, 2016 - nature.com
Ruxolitinib is a Janus kinase (JAK)(JAK1/JAK2) inhibitor that has demonstrated superiority
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with …
over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with …
Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study
RSM Wong, MN Saleh, A Khelif… - Blood, The Journal …, 2017 - ashpublications.org
Abstract In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with
chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced …
chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced …
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
E Rumi, D Pietra, V Ferretti, T Klampfl… - Blood, The Journal …, 2014 - ashpublications.org
Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a
calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential …
calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential …
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
E Rumi, D Pietra, C Pascutto… - Blood, The Journal …, 2014 - ashpublications.org
We studied the impact of driver mutations of JAK2, CALR,(calreticulin gene) or MPL on
clinical course, leukemic transformation, and survival of patients with primary myelofibrosis …
clinical course, leukemic transformation, and survival of patients with primary myelofibrosis …
A pilot study of the telomerase inhibitor imetelstat for myelofibrosis
A Tefferi, TL Lasho, KH Begna… - … England Journal of …, 2015 - Mass Medical Soc
Background Current drugs for myeloproliferative neoplasm–associated myelofibrosis,
including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions …
including Janus kinase (JAK) inhibitors, do not induce complete or partial remissions …